Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NASDAQ | Common Stock
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.
The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients.
Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications.
The company was founded in 2014 and is based in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 14, 24 | -0.35 Increased by +51.39% | -0.39 Increased by +10.26% |
| Mar 19, 24 | -0.69 Increased by +4.17% | -0.69 |
| Nov 8, 23 | -1.16 Decreased by -118.87% | -0.74 Decreased by -56.76% |
| Aug 9, 23 | -0.75 Decreased by -33.93% | -0.68 Decreased by -10.29% |
| May 9, 23 | -0.72 Decreased by -820.00% | -0.69 Decreased by -4.35% |
| Mar 15, 23 | -0.72 Decreased by -53.19% | -0.28 Decreased by -157.14% |
| Nov 8, 22 | -0.53 Decreased by -20.45% | -0.53 |
| Aug 10, 22 | -0.56 Decreased by -64.71% | -0.45 Decreased by -24.44% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 0.00 Increased by +100.00% | -29.49 M Decreased by -4.93% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -49.88 M Decreased by -137.47% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -32.40 M Decreased by -44.86% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by -100.00% | -29.63 M Decreased by -741.55% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | -24.99 M Decreased by -557.02% | -28.10 M Decreased by -77.72% | Increased by +112.46% Increased by +138.89% |
| Sep 30, 22 | 0.00 Decreased by -100.00% | -21.01 M Decreased by -49.91% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by -100.00% | -22.37 M Decreased by -106.09% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 24.99 M Increased by +727.73% | 4.62 M Increased by +121.66% | Increased by +18.48% Decreased by -96.55% |